An “AI-enabled” label is a starting point for a medical-technology conversation. For a hospital team assessing a proposal, the more useful discussion concerns what the technology is intended to do, the evidence behind its claims and the responsibilities that continue after installation.
On 14 October 2026, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) published its strategy to 2030. The agency announced plans for a Centre for AI and Digital Health and an adaptive approach to regulating AI as a medical device. These are strategic commitments for future work. Read the MHRA announcement, published 14 October 2026.
Our procurement perspective is to make three questions part of the specification and supplier discussion.
1. What is the intended use?
Ask for a clear description of the task, intended users and setting. Which part of the hospital workflow would the proposed technology support? What falls outside its stated purpose? Record the exact product and software version under discussion, so that demonstrations, supporting documents and quotations refer to the same proposal.
2. What evidence supports this specific claim?
Request the evidence relevant to the function being proposed. A presentation about a broad technology category should lead to documentation about the particular product and use being considered. Ask the supplier to identify the study or evaluation, its setting and limitations, and whether the evidence relates to the offered version.
Keep the clinical team involved in assessing clinical claims. Procurement can help by organising the questions, recording answers and making unresolved points visible before a commercial commitment.
3. Who manages changes and ongoing support?
Include software updates, training, technical support and escalation contacts in the buying conversation. Ask who communicates changes, what information accompanies an update and how the institution can maintain a record of the version in use. Clarify any dependencies on connectivity, existing systems and recurring licences in the written proposal.
Putting the update in context for Pakistan
The MHRA announcement concerns UK regulatory strategy. It does not establish Pakistani approval for any device, announce local availability or identify a product supplied by Elysian Biomedical LLP. Any proposed purchase needs its own product documentation and applicable local regulatory checks.
Elysian Biomedical LLP imports and distributes medical devices and supplies public and private hospitals across Pakistan. We follow international developments to support informed, specific conversations about hospital requirements. For AI-related proposals, our practical starting point remains intended use, relevant evidence and clear support responsibilities.
Further reading: MHRA Strategy 2030: Executive summary, published 14 October 2026. Sources reviewed on 19 October 2026.
Image: AI-generated illustration of a generic medical workspace; no real patient data, Elysian facility or specific product is depicted.
